

# Special Issue

## Microbiome and Pneumonia

### Message from the Guest Editors

There is plenty of evidence of existing microorganisms in the lungs that can correlate with the pathogenesis and development of chronic lung diseases, such as asthma, chronic obstructive pulmonary disease, interstitial lung disease, lung cancer, etc. Recent studies have shown that the gut microbiome affects an immune response in pneumonia. The gut dysbiosis that can be caused by lung dysbiosis mutually, which is called the gut–lung axis, contributes to the severity of pneumonia and clinical outcome. Furthermore, gut dysbiosis can contribute to decreasing antibody production after pneumococcal vaccination among allergic patients, such as severe atopic dermatitis. This issue might have impacted the high mortality rate of invasive pneumococcal disease, even though the patients were vaccinated with the pneumococcal vaccine. Modulating the dysbiosis in the lung and gut can be an essential treatment for pneumonia to improve the outcomes in patients with dysbiosis conditions. This review focuses on how the microbiome affects pneumonia's pathogenesis and clinical outcomes.

### Guest Editors

Dr. Nobuhiro Asai

1. Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute 480-1103, Japan
2. Department of Pathology, University of Michigan, Ann Arbor, MI 48105, USA

Prof. Dr. Hiroshige Mikamo

Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute 483-1195, Japan

### Deadline for manuscript submissions

closed (15 December 2023)



## Microorganisms

an Open Access Journal  
by MDPI

Impact Factor 4.2  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/154871](https://mdpi.com/si/154871)

*Microorganisms*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[microorganisms@mdpi.com](mailto:microorganisms@mdpi.com)

[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)





## Microorganisms

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
microorganisms](https://mdpi.com/journal/microorganisms)



## About the Journal

### Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

---

### Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for  
Environmental Research, 04318 Leipzig, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).